Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: IOVA

Iovance Biotherapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for IOVA. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (FY2025)$-1.09

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 09:46 UTC.

What Iovance Biotherapeutics, Inc. does

Iovance is a biopharmaceutical company developing tumor infiltrating lymphocyte, or TIL, cell therapies to treat solid tumor cancers. The company's lead commercial product is Amtagvi, a one-time individualized T cell therapy approved in the U.S. and Canada for previously treated advanced melanoma, which is administered with lymphodepletion and a short course of Proleukin. Amtagvi is manufactured using centralized, scalable processes at the company's FDA-approved facility in Philadelphia and is delivered through a growing network of authorized treatment centers.

Summarized from Iovance Biotherapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (FY2025)$-1.09

Revenue, margins & earnings

FY2023: net loss $444M on revenue $1M$1MFY2023FY2024: net loss $372M on revenue $164M$164MFY2024FY2025: net loss $391M on revenue $264M$264MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-02
  • 2026-10-02Chief Medical OfficerPerformance Stock UnitsAward135,000—
  • 2026-10-02Chief Medical OfficerStock Options (Right to Buy)Award135,000—
  • 2026-10-02Chief Medical OfficerRestricted Stock UnitsAward180,000—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Iovance Biotherapeutics, Inc. do?

Iovance is a biopharmaceutical company developing tumor infiltrating lymphocyte, or TIL, cell therapies to treat solid tumor cancers.

When did IOVA last file with the SEC?

Iovance Biotherapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-07-02. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 09:46 UTC. This page is also available as JSON at /api/data?ticker=IOVA and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for IOVA and 5,000+ tickers.

Create a free account — keep IOVA
For your agent
GET /api/data?ticker=IOVA

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt